BayBG invests in AMW

The venture capital firm, with a focus on Bavarian companies, has invested €3.6m alongside UnternehmerTUM Fund and IBG Beteiligungsgesellschaft Sachsen-Anhalt's Risikokapitalfonds II.

Bayern Kapital, KfW Bank and AMW managing director Wilfried Fischer invested €1.4m in the round's first close, led by SHS Gesellschaft für Beteiligungsmanagement.

The fresh funding will be used to develop a new technology for controlled drug delivery and to market the existing product portfolio.

According to BayBG, the patch and implant systems segment is currently worth approximately €30bn and is experiencing dynamic growth.

UnternehmerTUM Fund is backed by European Investment Fund (EIF), the Competitiveness and Innovation Framework Programme of the European Union, the ERP-EIF Dachfonds and the LfA-EIF Dachfonds.

Company
Founded in 2008 and headquartered in Warngau, AMW is a pharmaceutical company specialising in drug delivery systems. The products, designed to treat cancer and nervous system disorders, deliver medication to patients via patches and implants. These treatments release drugs in a controlled manner adapted to the needs of patients. One product has already received approval while three further products are awaiting approval. Three final products are in the final stages of clinical development.

Endomedica is a wholly owned subsidiary of AMW, headquartered in Halle, which will be responsible for coordinating the technical and clinical development of controllable patch technology together with scientific institutions in the region.

People
Wilfried Fischer founded AMW. Otto Hopfner is an investment manager at BayBG. Timo Komulainen is managing partner of UnternehmnerTUM Fund. Martin Laub is an investment manager at IBG. Bernhard Schirmers is the managing director of SHS.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany
• Bayerische Beteiligungsgesellschaft mbH (BayBG)